Science Budget: A Zero-Sum Game

Bioscientist Royston turns his attention to creating a center in San Diego's crowded research community WASHINGTON--The debate is over, says presidential science adviser Allan Bromley. The federal science budget is a question of priorities. And for members of the United States scientific community, this means that from now on they must persuade the politically powerful that their cause is more worthy of precious federal dollars than the other domestic needs facing the country. Throughout the

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Bioscientist Royston turns his attention to creating a center in San Diego's crowded research community
WASHINGTON--The debate is over, says presidential science adviser Allan Bromley. The federal science budget is a question of priorities. And for members of the United States scientific community, this means that from now on they must persuade the politically powerful that their cause is more worthy of precious federal dollars than the other domestic needs facing the country.

Throughout the 1980s, as the federal deficit mounted, analysts argued about whether the scientific community should set clear priorities and risk the loss of funding for some projects or, instead, campaign for an overall increase in spending on science that would benefit all concerned. Now, with the ink barely dry on the 1991 federal budget, Bromley says that the first approach has carried the day. But he doesn't think that good science will suffer.

"It's clear now ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies